Moreover, the plasmatic fractions of BRAF mutations measured in the first week following the initiation of immunotherapy [10] might predict the response to PD-1 or CTLA-4 inhibitors in advanced melanomas [8,27,28]. This evidence concerns the gene BRAF and melanoma.